TrevogrumabUnderstand the science
How researchers defined low lean mass at the start of COURAGE
2 numbered sourcesSource years 2024, 2026
Peptides are short chains of amino acids held together by peptide bonds. Some recognize other molecules and alter signaling. Trevogrumab is a larger protein antibody that targets myostatin, a regulator of muscle mass. Investigators studied the antibody with semaglutide and examined whether the lean mass results differed in adults who entered the trial with low lean mass. [1, 2]
For the subgroup, the investigators used a scan-based definition involving appendicular lean mass relative to body mass index. Appendicular lean mass estimates lean tissue in the arms and legs. Relating it to a body-size measure changes the question from how much lean tissue a person has to how much they have in relation to their size. That was the imaging criterion used to define the starting subgroup in the sponsor’s report. [1]
The sponsor said the low-lean-mass group showed a greater loss of lean mass with semaglutide alone and numerically greater preservation with the addition of trevogrumab. A numerical pattern in a subgroup can help frame a subsequent study. How precisely the treatment difference can be estimated depends on the number of participants and how the analysis was carried out. The report describes this subgroup analysis as prespecified. [1]
A person’s scan measurement and their ability to walk or exert force are different assessments. The subgroup findings concern the starting imaging criterion and a change in lean mass. They do not establish an effect on disability, daily activities or a clinical diagnosis of sarcopenia. The separate COURAGE registry records the planned endpoints for the investigational combinations. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). (opens in a new tab)
clinicaltrials.gov↩ Back to text
